Trial Profile
A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications IgA nephropathy
- Focus Proof of concept; Therapeutic Use
- Acronyms SIGN
- Sponsors Rigel Pharmaceuticals
- 16 Jan 2019 Status changed from active, no longer recruiting to completed.
- 22 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 03 Apr 2018 Primary endpoint has not been met. (Mean change of proteinuria as measured by spot urine protein/creatinine ratio (sPCR)), as reported in a Rigel Pharmaceuticals media release.